Meniere Disease

• Abnormal endolymphatic fluid production and reabsorption: The endolymphatic sac functions as the primary site of endolymph reabsorption and immune surveillance. Pathophysiologic studies suggest dysfunction in ion transport mechanisms within the stria vascularis (cochlear epithelium) and endolymphatic sac epithelium, leading to excessive fluid accumulation. The stria vascularis normally maintains the high potassium concentration (140 mM) and positive endocochlear potential (+80 mV) essential for cochlear transduction through Na-K-ATPase and potassium secretion via KCNQ1 channels. Mutations in genes encoding these ion transporters (KCNE1, KCNQ1) have been identified in familial cases, suggesting that abnormal potassium recycling contributes to fluid accumulation.

• Altered aquaporin-2 water channel expression: Aquaporins are membrane water channels critical for maintaining fluid homeostasis. Dysregulation of aquaporin-2 (AQP2) in the endolymphatic sac epithelium impairs water reabsorption, leading to fluid retention. Inflammatory cytokines and genetic variants affecting aquaporin expression promote hydrops development.

• Immune-mediated inflammation: Mounting evidence implicates autoimmune mechanisms in Menière disease pathogenesis. The endolymphatic sac contains lymphoid tissue (analogous to mucosa-associated lymphoid tissue), and autoantibodies targeting inner ear antigens (heat shock protein 70, cochlin, type II collagen) have been detected in serum and perilymph of affected patients. T-cell infiltration within the endolymphatic sac and increased pro-inflammatory cytokines (TNF-α, IL-6, IL-8) promote epithelial dysfunction and fluid secretion. This autoimmune mechanism is supported by the frequent association with other autoimmune conditions and the clinical response to corticosteroids in some patients.

• Viral infection as a triggering agent: Primary or reactivated viral infection of the inner ear (cytomegalovirus, herpes simplex virus, varicella-zoster virus) may initiate inflammation in genetically predisposed individuals. Viral antigens trigger endolymphatic sac inflammation and breach of the blood-labyrinth barrier, initiating a cascade of immune responses that perpetuate hydrops.

• Disrupted blood-labyrinth barrier: The inner ear is protected by specialized tight junctions (claudins, occludin, ZO-1) maintaining selective permeability between perilymph and systemic circulation. In Menière disease, inflammatory mediators increase vascular permeability, allowing fluid and immune cells to infiltrate the perilymphatic space and endolymphatic sac, exacerbating hydrops and triggering recurrent attacks.

• Mechanical effects of endolymphatic hydrops on vestibular and cochlear function: The physical distension of the membranous labyrinth causes several direct consequences:
• Cupular dysfunction: Bulging of the cupula (gelatinous structure overlying hair cells in ampullae of semicircular canals) increases its mechanical stiffness and shifts its resting position, causing spontaneous nystagmus and vertigo. The distended utricle and saccule may herniate into the cochlear duct, mechanically interfering with cochlear function.
• Cochlear dysfunction: Increased endolymphatic pressure compresses cochlear sensory epithelium, reducing hair cell transduction efficiency and causing low-frequency hearing loss, tinnitus (via altered neural firing patterns), and aural fullness (sensation caused by pressure changes).
• Episodic acute worsening: Rupture of Reissner's membrane (the thin barrier separating endolymph from perilymph) causes acute mixing of high-potassium endolymph with low-potassium perilymph, massively depolarizing vestibular and cochlear hair cells and triggering acute vertigo, hearing fluctuation, and intense tinnitus. Spontaneous resealing of the membrane explains the self-limited nature of acute attacks.

• Genetic predisposition: Family history is present in 5–10% of cases (familial Menière disease). Linkage studies have identified loci on chromosomes 12q24, 4p15, and 1q41, with specific mutations in KCNE1 and KCNQ1 affecting ion channel function in the stria vascularis. These genetic variants likely confer susceptibility to hydrops development when combined with environmental triggers.

• Endolymphatic sac dysfunction and impaired immune regulation: The endolymphatic sac expresses markers of immune tolerance (foxp3+ regulatory T cells, IL-10 production). Loss of immune tolerance, possibly through impaired regulatory T-cell function or aberrant Th17 differentiation, may permit autoreactive lymphocytes to attack labyrinthine structures, perpetuating inflammation and hydrops.

• Idiopathic endolymphatic hydrops (primary Menière disease): The vast majority of cases (~90%) are primary, arising without identifiable secondary cause. These patients meet clinical diagnostic criteria and presumably develop hydrops through the convergence of genetic susceptibility and environmental triggers (viral infection, allergic rhinitis, stress). The absence of systemic disease distinguishes primary from secondary Menière disease.

• Secondary endolymphatic hydrops: A small subset of patients develops hydrops as a consequence of known inner ear pathology or systemic disease. Secondary causes include:
• Syphilitic labyrinthitis (otosyphilis): Treponema pallidum infection causes persistent inflammation and fibrosis of the endolymphatic sac, obstructing reabsorption. Syphilitic patients typically present with bilateral involvement, positive serologies, and cerebrospinal fluid pleocytosis.
• Hypothyroidism: Chronic thyroid hormone deficiency impairs metabolic function in the stria vascularis and endolymphatic sac epithelium, promoting fluid accumulation. Thyroid hormone (particularly T4) regulates ion channel expression and epithelial tight junction integrity.
• Allergic rhinitis and chronic sinusitis: Elevated histamine from mast cell degranulation increases vascular permeability and promotes endolymphatic sac inflammation. Eustachian tube dysfunction from chronic rhinosinusitis impairs middle ear pressure regulation, indirectly affecting inner ear fluid dynamics.
• Post-traumatic hydrops: Labyrinthine concussion from head trauma can initiate chronic inflammation and hydrops development, sometimes with latency of months to years.
• Autoimmune inner ear disease (AIED): While distinct from Menière disease, AIED causes bilateral hydrops and hearing loss through aggressive autoimmune attack. Serum autoantibodies (anti-68 kDa, anti-HSP70) and elevated inflammatory markers differentiate AIED from Menière disease.

• Risk factors augmenting Menière disease manifestations:
• Salt sensitivity: High dietary sodium intake exacerbates fluid retention in genetically predisposed individuals through osmotic effects on endolymphatic fluid balance. A low-sodium diet is empirically recommended.
• Caffeine and alcohol: These substances alter vasomotor tone and may destabilize fluid homeostasis in the susceptible labyrinth. Avoidance is commonly advised.
• Stress and psychological factors: Psychological stress activates the hypothalamic-pituitary-adrenal axis and increases circulating catecholamines and corticotropin-releasing hormone, which modulate immune function and potentially trigger disease flares. Stress is a reported precipitant in >60% of patients.
• Migraine: A strong epidemiologic association exists between migraine and Menière disease (odds ratio 2–5), suggesting shared pathophysiologic mechanisms involving vasomotor instability and neuroinflammation. Patients with migraine and vertigo require careful evaluation for both conditions.
• Menstrual cycle: Some women report increased attack frequency during specific phases of the menstrual cycle, implicating hormonal modulation of immune and vascular responses.

• Episodic vertigo (hallmark symptom): Vertigo is rotatory/spinning in nature and represents the most disabling symptom. Attacks are spontaneous and unpredictable, typically lasting 20 minutes to several hours (range: 20 minutes to 24 hours). The vertigo is peripheral in nature (resulting from labyrinthine dysfunction) and is invariably accompanied by nausea and vomiting of sufficient severity to incapacitate the patient during the acute episode. Pathophysiologically, vertigo arises from acute depolarization of vestibular hair cells due to endolymphatic hydrops or membrane rupture, generating abnormal vestibular signals that the central nervous system interprets as rotatory head motion. The unpredictability and intensity create significant psychological distress and fear of future attacks ("vertigo anxiety"). Between attacks, the patient is completely symptom-free with no residual vestibular deficit, which distinguishes Menière disease from vestibular neuritis or superior semicircular canal dehiscence.

• Fluctuating, progressive sensorineural hearing loss: Hearing loss in early Menière disease is fluctuating and reversible, particularly affecting low frequencies (125–1000 Hz), consistent with cochlear hydrops affecting the apex (low-frequency region) of the cochlea. Early in disease, hearing may normalize between attacks, but with repeated episodes, permanent cumulative hearing loss develops. Over years, the audiogram evolves to a flat or high-frequency loss pattern as damage becomes widespread. The pathophysiology involves mechanical stress on cochlear hair cells from endolymphatic pressure and/or disruption of ion gradients when endolymph mixes with perilymph. Approximately 50–70% of untreated patients develop significant hearing loss (>30 dB) within 5 years of symptom onset. The early predominance of low-frequency loss is a key feature distinguishing Menière from noise-induced hearing loss (which preferentially affects 3–6 kHz frequencies).

• Tinnitus: Tinnitus—a subjective sensation of sound in the absence of external stimulus—is present in >90% of patients with Menière disease. The tinnitus is often low-frequency roaring or rushing in character, may fluctuate with vertigo episodes, and frequently worsens during acute attacks. Pathophysiologically, tinnitus arises from abnormal spontaneous firing of vestibular and cochlear nerve fibers triggered by endolymphatic hydrops and hair cell depolarization. The fluid pressure and mechanical distortion of the organ of Corti alter the resting discharge rate of cochlear neurons, creating phantom auditory signals. Some patients report that tinnitus intensity predicts impending vertigo attacks, serving as a warning sign.

• Aural fullness (autophony, fullness sensation): Patients describe a sensation of pressure, fullness, or "blocked ear" in the affected ear, often accompanied by autophony (abnormal perception of one's own voice or breathing sounds as loud or distorted). This symptom reflects the physical distension of membranous labyrinthine structures and altered middle ear pressures. Aural fullness frequently fluctuates with attack frequency and may persist chronically. The pathophysiology involves both mechanical bulging of the membranous labyrinth (which indirectly affects middle ear pressure transduction) and altered impedance matching of the ossicular chain.

• Acute attack characteristics: Attacks have a stereotyped temporal pattern within individual patients but vary widely between patients. A typical attack begins with sudden onset of severe vertigo (often with the patient in supine position or upon first head movement), accompanied by intense nausea and vomiting that forces the patient to lie motionless for hours. Nystagmus (typically rotatory-horizontal with the fast phase away from the affected ear) is present during acute attacks. Hearing often fluctuates during the attack, and tinnitus intensity increases. As the attack resolves over hours, vertigo gradually subsides, nausea abates, and the patient recovers complete vestibular function. Critical clinical distinction: Between attacks, neurologic examination is completely normal, including normal caloric responses and intact vestibular-ocular reflex. This inter-attack normalcy is pathognomonic for Menière and contrasts sharply with central vestibular disorders or chronic vestibulopathy.

• Attack frequency and disease course: Early in disease (first attack to first year), attacks are infrequent and may be separated by months. Over time, attack frequency increases, with some patients experiencing clusters of multiple attacks over days to weeks. Later in disease course (years 5–15), some patients paradoxically experience decreased attack frequency as hearing loss progresses, possibly due to "burnout" of vestibular end-organs. The disease is remitting-relapsing in most patients, with unpredictable periods of relative quiescence alternating with active phases.

• Physical examination findings: The between-attack neurologic examination is entirely normal, including normal otoscopy, normal caloric testing, normal electromystagraphy, and normal hearing on formal audiometry (early in disease). The presence of any neurologic abnormality should prompt investigation for alternative diagnoses. During acute attacks, spontaneous nystagmus may be observed, typically horizontal-rotatory with the quick phase directed away from the affected ear. Positive Romberg test may occur during acute attacks due to vestibular dysfunction, but postural stability is normal between attacks.

• Important clinical variants and atypical presentations:
• Cochlear variant (cochlear hydrops): Isolated hearing loss and tinnitus without vertigo in a patient with documented hydrops on imaging. This represents incomplete disease expression in ~5% of cases.
• Vestibular variant (vestibular Menière): Recurrent vertigo attacks without significant hearing loss. May represent early disease or selective vestibular end-organ involvement.
• "Lermoyez syndrome": Sudden hearing improvement during or immediately after a vertigo attack, presumably due to resolution of pressure-induced hair cell dysfunction. This dramatic reversal occurs in <5% of patients and may reflect rupture and resealing of Reissner's membrane.
• Bilateral Menière disease: Occurs in 15–30% of cases, either synchronously or with involvement developing sequentially in the contralateral ear over years. Bilateral disease presents diagnostic and therapeutic challenges.

• Diagnostic criteria and classification (AAO-HNS 1995 guidelines):
• Definite Menière disease: All of the following criteria must be met:

1. 1.Two or more spontaneous episodes of vertigo lasting 20 minutes to 24 hours
2. 2.Audiometrically documented hearing loss on at least one occasion (sensorineural loss at frequencies ≤3 kHz or across frequencies)
3. 3.Fluctuating symptoms related to the affected ear (hearing, tinnitus, aural fullness)
4. 4.Other causes excluded by appropriate investigation

• Probable Menière disease: One of the following combinations:

1. 1.Two or more episodes of vertigo lasting 20 minutes to 24 hours with hearing loss but without documented fluctuation
2. 2.Fluctuating hearing loss with episodic vertigo-like symptoms (but not definite vertigo)
3. 3.Hearing loss and other otologic symptoms with vertigo-like symptoms

Acute attack (symptom control only, days not weeks)

• Vestibular suppressants: antihistamine/anticholinergic meclizine, or a benzodiazepine (diazepam) for severe spinning; both blunt vestibular nucleus output.
• Antiemetics: ondansetron or promethazine; IV fluids if vomiting is intractable.
• Rule out stroke first in a patient with acute continuous vertigo: a bedside HINTS examination and focused neurologic exam. Menière attacks are episodic and the inter-attack exam is normal, so any persistent central sign demands urgent posterior-fossa imaging (MRI, not CT).

First-line maintenance (AAO-HNS Foundation 2020 Clinical Practice Guideline: Ménière's Disease)

• Dietary sodium restriction and trigger avoidance (caffeine, alcohol, tobacco, stress) — the guideline endorses patient education and lifestyle modification as initial therapy.
• Diuretics: thiazide or thiazide-like agents, classically hydrochlorothiazide–triamterene, offered as an option to reduce attack frequency by lowering endolymphatic fluid volume.
• Treat comorbid migraine when vertigo has migrainous features, since the two overlap substantially.

Escalation when attacks persist

• Intratympanic corticosteroids: dexamethasone injected through the tympanic membrane — hearing-preserving, offered before any ablative step.
• Vestibular rehabilitation: for chronic imbalance between attacks, not for the acute attack.
• Amplification: hearing aids, or cochlear implantation for profound loss.

Ablative/definitive options (unilateral, medically refractory disease)

• Intratympanic gentamicin: selective chemical vestibulotoxicity (chemical labyrinthectomy); controls vertigo but risks further hearing loss.
• Endolymphatic sac decompression/shunt: hearing-preserving surgical option.
• Vestibular nerve section: high vertigo control with hearing preservation, but craniotomy-level risk.
• Labyrinthectomy: most definitive, sacrifices all hearing — reserved for a non-serviceable ear.

Avoid, and low-value options

• Ablative therapy in bilateral disease or an only-hearing ear — produces bilateral vestibular loss with oscillopsia.
• Chronic vestibular suppressants — they block central vestibular compensation and cause sedation, falls, and anticholinergic delirium in older adults.
• Positive-pressure (Meniett) device: the AAO-HNS 2020 guideline explicitly advises clinicians not to routinely prescribe it.
• Betahistine: a histamine analog offered by the same guideline only as a weak option supported by low-quality evidence (including a negative randomized trial), and not available as an FDA-approved product in the United States — so it is not the expected answer on a US exam, though the guideline does not recommend against it.

Disease-related

• Progressive sensorineural hearing loss: repeated hydrops and potassium intoxication of hair cells cause cumulative damage; signalled by an audiogram that no longer normalizes between attacks and evolves from low-frequency to flat/high-frequency loss.
• **Tumarkin otolithic crisis (drop attack): abrupt mechanical deformation of the utricular/saccular otolith organs triggers a sudden loss of postural tone — the patient falls to the ground without loss of consciousness or vertigo prodrome**. High risk of head injury and fracture; mandates driving restriction and prompt escalation of therapy. Syncope with true loss of consciousness is not Tumarkin and should be worked up as cardiac.
• Bilateral disease and chronic vestibular hypofunction: loss of both labyrinths produces oscillopsia (bouncing vision with head movement) and gait ataxia worse in the dark — irreversible.
• Psychiatric morbidity: anxiety, panic, agoraphobia and depression from unpredictable attacks; a leading driver of disability.
• Missed alternative diagnosis: unilateral SNHL with imbalance may be vestibular schwannoma; persistent central signs (direction-changing nystagmus, skew deviation, normal head impulse test) suggest posterior circulation stroke — an emergency.

Treatment-related

• Intratympanic injection: persistent tympanic membrane perforation, otitis media, transient vertigo/dizziness after injection.
• Intratympanic gentamicin: aminoglycoside hair-cell toxicity causing worsened sensorineural hearing loss and, if given bilaterally, permanent bilateral vestibulopathy.
• Labyrinthectomy: complete, permanent deafness in the operated ear by design.
• Vestibular nerve section: CSF leak, facial nerve injury, and postoperative meningitis — an emergency (fever, headache, neck stiffness after otologic surgery).
• Diuretics: the thiazide component causes hypokalemia and hyponatremia (plus orthostatic hypotension and hyperuricemia), while the potassium-sparing triamterene component can instead cause hyperkalemia, particularly with chronic kidney disease, concurrent ACE inhibitor/ARB, or potassium supplements. Follow a basic metabolic panel after initiation and with dose changes.
• Chronic vestibular suppressants: sedation, falls, anticholinergic delirium in the elderly, benzodiazepine dependence, and blunted central compensation.

• The tetrad wins the question: episodic spontaneous vertigo + fluctuating sensorineural hearing loss + low-frequency roaring tinnitus + aural fullness, with a completely normal exam between attacks.
• Know the current duration cutoffs (2015 Bárány Society/AAO-HNS consensus criteria, adopted by the AAO-HNS 2020 guideline): definite Ménière disease = ≥2 spontaneous vertigo episodes lasting 20 minutes to 12 hours, with audiometrically documented low- to mid-frequency SNHL in the affected ear and fluctuating aural symptoms; probable disease = episodes lasting 20 minutes to 24 hours. The older 20-minute-to-24-hour definite threshold is 1995 AAO-HNS language and is historical.
• Low-frequency loss is the audiometric fingerprint. Noise-induced loss notches at 3–6 kHz and presbycusis is high-frequency; a *low*-frequency sensorineural dip points to hydrops.
• Single best next step for a suspected first presentation: audiometry — hearing loss must be audiometrically documented to meet criteria. If loss is unilateral and progressive, obtain MRI of the internal auditory canals with gadolinium to exclude vestibular schwannoma (the classic distractor).
• Initial management is conservative — sodium restriction and trigger avoidance, with a diuretic offered as an option (AAO-HNS 2020, low-quality evidence) — not surgery and not chronic meclizine. Vestibular suppressants are for the acute attack only, since chronic use blocks central compensation.
• The association examiners love: migraine. Vestibular migraine is the most common mimic; recurrent vertigo with photophobia, headache, and normal audiometry is migraine, not Menière.
• Duration is the discriminator: seconds to <1 minute with positional trigger and a positive Dix–Hallpike = BPPV; a single prolonged episode over days without hearing loss = vestibular neuritis; days-long vertigo with hearing loss = labyrinthitis; recurrent minutes-to-hours attacks with hearing loss = Menière.
• Tumarkin otolithic crisis: sudden fall without loss of consciousness or warning — a Menière complication, not syncope and not a seizure.
• Ablation is unilateral only: gentamicin or labyrinthectomy in bilateral disease or an only-hearing ear produces oscillopsia and deafness.
• Betahistine is not the US answer — it lacks FDA approval and commercial availability here, and the 2020 guideline lists it only as a weak, low-evidence option. The Meniett positive-pressure device is what the guideline actually advises against.